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a  b  s  t  r  a  c  t
Aim: The aim of the present study was to analyze the age of breast cancer patients managed
with  curative approach at the time of treatment with radiotherapy.
Background: Breast cancer is the most frequent neoplasm in women. Little is known with
regard to the age of patients at diagnosis, and some authors have suggested that breast
cancer is now affecting women who are younger than before.
Materials and methods: We  performed a descriptive study of our series of breast cancer
patients from 1998 to 2011. The age of patients, city of residence, year of treatment and
uni-  or bilateral location were extracted from the administrative database of the Radiation
Oncology Department. The demographical and reference populational data were extracted
from  the Catalan Institute of Statistics.
Results: 3382 patients were obtained. The mean age was 57.79 years. No statistical differenceswere observed in the mean age during the period of study (p > 0.05), nor in patients with
bilateral neoplasias with regard to unilateral tumours (p > 0.5). Patients aged less than 30,
40,  50 and 65 years were 0.3%, 6.3%, 27.0% and 69.1%, respectively. The proportion of patients
aged less, equal or more than 40 and 50 years was not statistically different.
Conclusions: Breast cancer patients treated with adjuvant radiotherapy after radical surgeryhave not experienced signiﬁcant changes in their mean age at treatment. The subgroups
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of patients that remain out of the mammographic screening programmes were unchanged
as  well. The observed differences can be explained by demographical disparities and by a
probable increase in the indications for adjuvant radiotherapy.














































reast cancer is the most frequent neoplasm in women. It rep-
esents 28% of female cancer cases in Catalonia (Spain) with
n incidence of 97.3 and 99.3 new cases per 100 000 women,
ccording to the population registries of Tarragona and Girona,
espectively (data from 1998 to 2002). In 2002 the estimated
ncidence was of 3829 cases which is expected to rise to 6482
ew cases in 2019.1 Fortunately, breast cancer deaths declined
y 3% per year in Catalonia between 1993 and 2007.2 A recent
nalysis of 2023 women with incident invasive breast cancer
ollected from 1992 to 2005 in an institutional cancer reg-
stry in Barcelona (Catalonia, Spain), showed that the 5-year
isease-speciﬁc survival rate increased from 73.5% to 86.4%
log rank, p < 0.001).3
However, there is a lack of recent data in describing pos-
ible age variations at diagnosis of breast cancer patients. To
ur knowledge, the only previous study was conducted by the
eneva Cancer Registry (Switzerland), motivated by the feel-
ng of some health professionals that breast cancer incidence
as increasing in younger patients. The study showed an 8.7%
nnual increase in breast cancer incidence for women aged
ess than 40 years in the period from 2002 to 2004.4
While the “Vallès Occidental” region holds the second
ighest rates of population density in Catalonia, the area
acks a population cancer registry. Cancer incidence estimates
n Catalonia come from the population registries of Tarrag-
na and Girona that cover approximately 20% of the whole
atalan population. It is well known that adjuvant radiation
herapy (ART) for breast cancer can reduce by half the risk
f recurrence and by a sixth the probability of death.5,6 In
ddition, ART in breast cancer patients is advisable for approx-
mately 83% of all surgically treated patients.7 So, as matter
f the high percentage of breast cancer patients that receive
adiotherapy, the objective of this study was to describe the
ge distribution of breast cancer patients treated with ART
ith the aim of deﬁning the possible variations in the age
t treatment of breast cancer patients during the last 10
ears.
.  Materials  and  methods
his is a descriptive epidemiological study of a series of
reast cancer patients treated with adjuvant radiation ther-
py in the region of the Vallès Occidental (Catalonia, Spain)
hat has a population of about 900 000 inhabitants. The study
ncluded patients coming from the following municipalities in
he region: Badia del Vallès,  Barberà del Vallès,  Castellar del Val-
ès, Castellbisbal, Cerdanyola del Vallès,  Matadepera, Palau-solitài Plegamans,  Polinyà,  Ripollet, Rubí, Sabadell, Sant Cugat de Vallès,
Sant Llorenc¸ de Savall,  Sant Quirze del Vallès,  Santa Perpètua de
Mogoda, Sentmenat,  Terrassa, Ullastrell, Vacarisses and Viladecav-
alls. We extracted the administrative data of the correlative
patients treated from 1st January 1998 to 31st December
2011 at the Radiation Oncology Department of the Institut
Oncològic del Vallès,  at Sant Cugat headquarters. The patients
come referred from the main hospitals in the region: Cor-
poració Sanitària Parc Taulí (Sabadell, Barcelona), the Consorci
Sanitari de Terrassa and Mutua de Terrassa (Terrassa, Barcelona).
Population accounts were extracted from the Catalonian
Statistics Institute website.8 Due to logistic reasons, some
patients meeting the inclusion criteria (135) were referred
for treatment to the RT Department of the Parc de Salut
Mar  (Barcelona). Those patients were counted when calculat-
ing the rates of RT treatments performed during the last 10
years.
2.1.  Participants,  procedures,  variables,  and  measures
We  obtained a sample of 3382 patients during 10 years. Due
to the administrative nature of the extracted data, neither
clinical nor private information was obtained from clinical
reports.
Inclusion criteria were: (1) female sex, and (2) ﬁrst treat-
ment with radiotherapy to the breast or chest wall. Exclusion
criteria were: (1) male sex, and (2) palliative approach.
Study variables were: (1) the age of patients when the radio-
therapy treatment began, (2) the year of RT administration, (3)
laterality (unilateral or bilateral, in spite of a synchronic or
metachronic diagnosis), (4) city of residence, and (5) inhabi-
tants per city.
Data were stratiﬁed by age groups at thresholds of 40, 50
and 65 years.
2.2.  Data  analysis
We  began with descriptive analyses to characterize the study
population. The obtained sample easily led us to obtain a wide
3% of accuracy (e) for an error alpha of 0.05, based on the prob-
ability of being diagnosed with breast cancer at an age under
45 years (12.1%9). The qualitative variables were characterized
by proportions and an interval of conﬁdence (IC) of 95%. Quan-
titative variables were characterized by means and standard
deviation (DE).Statistical differences were analyzed by the t-Student test,
2 or by ANOVA with a signiﬁcation degree (p) of less than 0.05.
The statistical analysis was performed with the software
Stata v10.110 and OpenEpi.11
nd radiotherapy 2 0 ( 2 0 1 5 ) 22–26
Table 2 – Mean age of patients in the group of 50–65
years-old along the period of study. Std. Dev.: standard
deviation. Obs: observations.
Year Mean (age) Std. Dev. Obs.
1998 58.19 12.59 118
1999 58.98 12.60 119
2000 56.54 13.20 128
2001 59.84 12.18 129
2002 57.10 12.53 143
2003 57.01 11.97 270
2004 56.12 11.95 243
2005 57.35 13.07 240
2006 57.68 12.48 274
2007 57.43 12.03 283
2008 58.33 12.04 377
2009 58.90 12.15 376
2010 57.17 11.82 367
than 40 and 50 years. The mean age of treated patients was24  reports of practical oncology a
3.  Results
In the period of study 3382 patients were treated with adjuvant
RT after curative surgery. The mean age for all patients was
57.79 years (SD = 12) ranging from 25 to 96 years.
Approximately half of the patients came from both the
biggest cities of Sabadell and Terrassa. The mean age for all
patients ranged from 52.87 to 66.30 years. We  found statistical
differences between cities only when comparing the minimal
(from Barberà del Vallès,  X = 52.87; SD = 11.43) with the maxi-
mal  mean age (from Sant Llorenc¸ de Savall X = 66.3; SD = 14.69;
p < 0.001).
The observed mean age of patients per year is shown in
Fig. 1. The ANOVA analysis did not reveal signiﬁcant differ-
ences in the mean age of patients treated during the study
period (p > 0.05).
Fifty-three patients (1.5%) had bilateral tumours either
synchronous or metachronous. The t-test for independent
samples failed to show signiﬁcant differences in the mean
age of these patients (X = 58.24 years-old; SD = 10.51) compared
to those with unilateral disease (X = 7.79 years-old; SD = 14.69;
p > 0.5).
The region Vallès Occidental also experienced a population
increase during the last decade.8 We  studied the correlation
between the number of patients treated and the female pop-
ulation of the region for the last 10 years, which was found to
be strong (coefﬁcient = 0.943). In addition, there was a notable
increase in the number of treatments performed since 2002
(Fig. 2).
The proportion of patients under the age of 30, 40, 50 and
65 years was of 0.3% (12 patients), 6.3% (214 patients), 27% (915
patients) and 69.1% (2338 patients), respectively. The number
of patients aged less; equal or more  than 40 and 50, did not
show a signiﬁcant modiﬁcation across the period. We only
observed a higher number of treated women aged less than 65
years for the periods 2004 and 2007. For the remaining periods,
these differences were not statistically signiﬁcant (Table 1).
Among the women treated with adjuvant RT at ages
between 50 and 65 years (target ages for mammographic
screening), the ANOVA analysis did not show signiﬁcant dif-
ferences either (p > 0.05) (Table 2).
Table 1 – Odds ratio (OR), 95%CI conﬁdence interval and level of
equal or superior to 40, 50 and 60 years-old.
Year <40 vs ≥40 years-old <50 vs
OR CI 95% p OR C
1999 1 1 
2000 0.51 0.19–1.30 0.16 0.60 0.
2001 1.95 0.55–7.77 0.31 1.22 0.
2002 0.75 0.27–2.01 0.58 0.73 0.
2003 0.78 0.30–1.86 0.61 0.92 0.
2004 0.66 0.25–1.57 0.37 0.72 0.
2005 0.88 0.33–2.16 0.80 0.77 0.
2006 0.75 0.29–1.78 0.55 0.78 0.
2007 0.98 0.37–2.38 0.98 0.83 0.
2008 1.32 0.50–3.22 0.54 0.93 0.
2009 1.06 0.41–2.49 0.88 1.10 0.
2010 1.03 0.40–2.43 0.92 0.84 0.2011 58.69 12.28 315
Total 57.80 12.27 3382
4.  Discussion
Our study describes the age of patients at the time of their ﬁrst
radiotherapy treatment for breast cancer in our region (Vallès
Occidental) through the last decade. The region experienced
a vast industrial transformation during the sixties showing a
peak of growth in 2004 in terms of economic output over Cata-
lan mean averages. Cancer is the leading cause of mortality in
Catalonia for women aged between 55 and 64 representing
more  than half of all deaths in this age group. In addition, an
increase of breast cancer incidence throughout the last decade
has been reported.15 Hence, some of our patients are worried
that these new environmental factors are playing a role in
cancer genesis and will translate to more  cancers in younger
people.
Although this is a descriptive study based on an institu-
tional sample, we  did not establish any modiﬁcation in the
proportion of breast cancer patients treated with ART younger57.79 years, which is slightly lower than the mean age at diag-
nosis observed by the Surveillance, Epidemiology and End
Results (SEER) in the United States for the period 2005–2009
 signiﬁcance of the number of patients at lower age vs
 ≥50 years-old <65 vs ≥65 years-old
I 95% p OR CI 95% p
1
34–1.04 0.07 0.80 0.45–1.41 0.43
67–2.22 0.52 1.04 0.60–1.81 0.90
42–1.26 0.25 0.73 0.42–1.27 0.29
55–1.51 0.75 0.66 0.40–1.05 0.06
43–1.19 0.20 0.51 0.31–0.85 0.01
46–1.26 0.30 0.76 0.47–1.24 0.28
47–1.27 0.33 0.78 0.49–1.26 0.30
50–1.36 0.47 0.62 0.38–1.00 0.04
57–1.49 0.78 0.89 0.57–1.39 0.58
67–1.78 0.69 0.84 0.53–1.32 0.44
51–1.34 0.47 0.66 0.41–1.04 0.07























tFig. 1 – Mean age and standard de
61 years),12 and the data published by the Tarragona Cancer
egistry for the period 1998–2001 (61.5 years). This difference
ould be explained by the fact that adjuvant RT could be mis-
sed in elderly patients, who are more  often treated with
urgery or hormone therapy alone,13 that would have biased
ownward the mean age at treatment found in our patients.
either did we  detect any signiﬁcant differences in the mean
ge at treatment of patients between 50 and 65 years-old (the
arget age for screening programmes in European countries).
owever, the administrative nature of our data does not allow
s to know how many  of these patients have been diagnosed
ia a screening programme that limits us to studying the
otential differences in age according to the diagnostic source.
We only observed mean age differences between munic-
palities, but these were secondary to the demographic
isparities for the last 10 years. For example, women living
n Sant Llorenc¸ de Savall are signiﬁcantly older than those from
arberà del Vallès (30% of females over 60 years compared with
7%, respectively).
Neither did we  observe signiﬁcant differences in the age of
atients treated with bilateral tumours compared to unilateral
resentation. The proportion of patients treated with bilateral
isease (either synchronous or metachronous) was 1.5% of the
otal treatments, fewer than 3.1% as reported by the breast
Fig. 2 – Number of curative/adjuvant treatments pion of patients from 1998 to 2011.
cancer screening programme from Sabadell-Cerdanyola for
the years 1995–2003.14 This source also reports 18.8% of “in
situ” neoplasms and 24.3% of small invasive lesions that also
show, in 80% of cases, good positive hormone receptors. So,
we consider that for the remaining half of patients not treated
with ART, some factors such as age, clinical conditions and/or
good prognosis of pathologic ﬁndings have probably led to a
more conservative approach.
In our study, the percentage of treated patients younger
than 40 and 50 years was 6.3% and 27.0%, respectively. These
results are consistent with the ﬁndings of an EBCTCG meta-
analysis6 that show a 4.99% and 20.87% of patients under 40
and 50 years, respectively. These ﬁndings are also in concord-
ance with the reported proportion of patients under the age
of 50 years (24.90%) at the population registry of Tarragona.15
The cancer registry of Geneva (Switzerland) documented
an increase in breast cancer incidence among younger
patients, of 8.7% per year in the period 2002–2004 for women
younger than 40.4 Unfortunately, our study cannot answer this
question and the results from our sample cannot be inferred
to the population. However, the fact that the proportion of
patients younger than 40 and 50 did not signiﬁcantly change
over the period of our study, would suggest a stability of the
behaviour of breast cancer in the region of the Vallès Occidental.
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The probability of developing breast cancer in the next
10 years is (excluding cases of family history or genetic dis-
orders) 1.4% starting at the age of 40, and 1.9% above 50.16
There is a debate about the appropriate age to start screening
programmes. While the U.S. advises to start an annual mam-
mography after 40, in most European countries mammograms
are biannual and start from the age of 50. In our study, we
found that the proportion of patients treated outside age for
mammographic screening in Spain (grouped either under 40
or 50 years) has not undergone signiﬁcant changes. Never-
theless, we found a trend towards a higher proportion of
patients younger than 65 years that may translate into a
group of patients that have beneﬁted from early diagnosis
in a screening programme. The programme for early detec-
tion of breast cancer in Catalonia started gradually from the
beginning of the nineties and was ﬁrst offered to women aged
50–64 years. Since 2000, it has been extended to women up
to 69 years. The screening programme in our region started
at Sabadell-Cerdanyola in 1995 with a good public response
(57–72%) and the coverage of the target population of 86.8%.17
The programme extended later, in May 2002, to the cities
of Terrassa les Fonts – Sant Quirze del Vallès,  Rubí, Sant Cugat,
Matadepera, Castellbisbal, Ullastrell and Viladecavalls, with an
initial uptake of 50% increasing to 73.6% in 2005, and achieving
the coverage of 60%.18 In consequence, this latter implemen-
tation would have justiﬁed the increase of RT treatments
observed from 2002. Moreover, the proportion of conservative
surgeries for breast cancer in Catalonia has increased from
60.3% in 2003 to 70.18% in 200919 that have also probably been
followed by an increase in the use of ART.
5.  Conclusions
Although we  cannot determine the real incidence of breast
cancer in our region from the current data, we can explain
some epidemiological features of breast cancer in the Vallès
Occidental.  The patients treated with adjuvant radiotherapy
after radical surgery have not experienced signiﬁcant changes
in their mean age at treatment, as well as the age of the
subgroups that are currently excluded from mammographic
screening programmes. The observed differences can be
explained by demographical disparities and also by a prob-
able increase in referrals for adjuvant radiotherapy during the
past decade.
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